A buyer of biopharmaceutical royalties: it pays universities, hospitals, foundations, and drugmakers upfront cash in exchange for a share of future sales of approved and late-stage medicines like Vertex's Trikafta cystic fibrosis treatment and Xtandi. Founded in 1996 by former Lazard banker Pablo Legorreta, who got the idea after watching a chemotherapy royalty investment pay off, it grew into one of the world's largest acquirers of drug royalty streams. Notably, it never develops drugs itself—it simply collects a slice of the top-line sales of treatments others make and sell.
A $472M swing to a non-cash provision expense drove operating income down 36.5% despite a 16.5% revenue increase.
A large non-cash provision charge reversed the prior year's gain, pulling reported earnings lower. rose 16.5% to $674.1 million, but fell 36.5% to $133.1 million as a $268.2 million provision expense replaced a $203.9 million provision income, driven by Adstiladrin and the cystic fibrosis franchise. The underlying cash generation grew, but non-cash accounting swings continue to dominate reported results.
Key takeaways
A $268.2 million was recorded in Q2 2026, a $472.1 million swing from the $203.9 million provision income in Q2 2025, primarily due to Adstiladrin and the cystic fibrosis franchise.
Total income and other revenues rose 16.5% to $674.1 million, led by a 15.9% increase in income from financial royalty assets, notably from Tremfya and the cystic fibrosis franchise.
, a key cash-generation metric, increased 6.3% to $773.0 million, with Royalty Receipts growth led by Voranigo, Tremfya, and Evrysdi.
Section summaries
Management's Discussion and Analysis
Total income rose 16.5% in Q2 2026 driven by Tremfya and cystic fibrosis, while a $268M provision expense swung operating income to a decline.
⌄
Total income and other revenues grew 16.5% to $674.1M in Q2 2026, led by a 15.9% increase in income from financial royalty assets, notably from Tremfya and the cystic fibrosis franchise.
R&D funding expense fell 67.4% to $97.9 million, as the prior-year period included a $250 million payment related to daraxonrasib.
General and administrative expenses decreased 9.9% to $161.9 million, reflecting the elimination of Management Fees after the Internalization, partially offset by higher .
rose 100.1% to $728.5 million, and to $1.45 billion for the first half of 2026, driven by lower development-stage funding payments and higher royalty cash collections.
What changed
The non-cash provision swung sharply negative: Q2 2025 recorded a $203.9 million provision income driven by improved forecasts for Evrysdi and Xtandi, but Q2 2026 recorded a $268.2 million expense as forecasts for Adstiladrin and the cystic fibrosis franchise declined, a $472.1 million reversal.
The $300.5 million R&D funding expense spike in Q2 2025, flagged as a watch item, proved to be a one-time event tied to daraxonrasib and litifilimab upfront payments; R&D funding expense fell 67.4% to $97.9 million in Q2 2026.
The $69.4 million Tazverik in Q1 2026, flagged as a potential signal of broader risk, did not repeat in Q2 2026, suggesting it was an isolated event tied to the product's voluntary market withdrawal.
The recurring G&A run-rate post-Internalization, a persistent watch item, declined 9.9% to $161.9 million from $179.8 million in Q2 2025, as the elimination of Management Fees began to outweigh the new costs.
The Vertex dispute over Alyftrek royalty payments, flagged in FY 2025 and Q1 2026, remains unresolved with no recovery recognized; the risk factor disclosure confirms formal dispute resolution procedures are ongoing.
What to watch
Whether the $268.2 million non-cash provision expense in Q2 2026 expands further if sell-side forecasts for Adstiladrin and the cystic fibrosis franchise continue to decline, or reverses if forecasts stabilize.
The recurring quarterly G&A run-rate now that the Internalization is complete—whether the $161.9 million in Q2 2026 represents the new baseline or will decline further as one-time transition costs fade.
Resolution of the Vertex dispute over Alyftrek royalty payments, and whether any recovery is recognized in 2026 given Vertex still represents a material concentration of financial royalty assets.
Contribution from the $885 million Imdelltra royalty and the $2 billion Revolution Medicines arrangement to , and whether they begin to reduce the 59% concentration in the top five product franchises.
A $268.2M provision for changes in expected cash flows was recorded in Q2 2026, a swing from $203.9M in provision income a year ago, primarily due to Adstiladrin and the cystic fibrosis franchise.
R&D funding expense fell 67.4% to $97.9M in Q2 2026, as the prior-year period included a $250M payment related to daraxonrasib.
G&A expenses decreased 9.9% to $161.9M in Q2 2026, reflecting the elimination of Management Fees after the Internalization, partially offset by higher .
, a key cash metric, increased 6.3% to $773.0M in Q2 2026, with Royalty Receipts growth led by Voranigo, Tremfya, and Evrysdi.
Cash provided by operating activities rose to $1.45B in H1 2026 from $960.1M, driven by lower development-stage funding payments and higher royalty cash collections.
Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in market risk exposures that affect the disclosures presented in “Item 7A. Quantitative and Qualitative Disclosures about Market Risk” in the Annual Report on Form 10-K for the year ended December 31, 2025.
⌄
There have been no material changes in market risk exposures that affect the disclosures presented in “Item 7A. Quantitative and Qualitative Disclosures about Market Risk” in the Annual Report on Form 10-K for the year ended December 31, 2025.
Royalty receipts are concentrated, dependent on marketer actions, and subject to development-stage, leverage, and tax risks that could materially reduce cash flows.
⌄
The top five product franchises generated 59% of Royalty Receipts in H1 2026, exposing the company to significant deterioration if cash flows from these products decline.
A dispute with Vertex over Alyftrek royalty payments has led to formal dispute resolution, with any recovery recognized only upon a favorable outcome.
Acquiring royalties on development-stage candidates carries high uncertainty, with past clinical failures leading to and future failures posing similar risks.
The company's $9.2 billion in debt magnifies losses if royalty assets underperform, and rising interest rates could increase borrowing costs and reduce net profits.
The company's status for U.S. tax purposes subjects U.S. shareholders to adverse tax consequences, including ordinary income treatment on gains and potential reporting penalties.
Marketers of products generating royalties are outside the company's control, and their strategic shifts, insolvency, or failure to maintain patent protection could reduce or cease royalty payments.